Helix BioPharma Corp. reported a net loss of $5,205,000 for the fiscal year ended July 31, 2025, representing a significant improvement from the $9,264,000 loss reported in the previous year. The company's loss per common share decreased to $0.09 from $0.21 in 2024, reflecting substantial progress in financial management despite ongoing clinical development challenges.
The company's strategic shift toward focusing resources on developing L-DOS47 as a combination therapy with PD-1 inhibitor pembrolizumab as first-line therapy for Non-Small Cell Lung Carcinoma (NSCLC) marks a critical development in cancer treatment research. This decision followed an extensive review of available pre-clinical and clinical data, assessment of unmet medical needs in NSCLC, and evaluation of where pharmacological tumor alkalization therapy could deliver meaningful clinical impact in the near term. The company received positive feedback from the U.S. Food and Drug Administration on the study design for LDOS007, its new Phase Ib/Randomized Phase II study assessing L-DOS47 in combination with pembrolizumab.
Research and development expenses decreased by 40% to $3,558,000 in fiscal 2025, primarily due to the conclusion of the Phase Ib/II study in metastatic pancreatic adenocarcinoma (LDOS006) and changes in collaborative research activities. Operating, general and administration expenses also decreased by 43% to $1,839,000, reflecting changes in service providers and operational efficiencies. The company's financial statements and management discussion are available through its SEDAR+ profile at https://www.sedarplus.ca/.
Corporate developments throughout the year included significant leadership changes, with Thomas Mehrling, MD, PhD appointed as Chief Executive Officer on April 10, 2025, and Rohit Babbar appointed as Chief Financial Officer on June 2, 2025. The company also completed several financing activities, including a private placement for gross proceeds of $3,000,000 on January 8, 2025, and the acquisition of Laevoroc assets through share issuance valued at approximately $18 million in May 2025.
The company's liquidity position remains challenging, with cash reserves of $65,000 as of July 31, 2025, insufficient to meet anticipated cash needs for the next twelve months. Management emphasized the importance of securing additional funds primarily through equity arrangements to continue research and development initiatives. The company's working capital deficiency stood at $2,807,000 with shareholders' deficiency of $15,586,000 and accumulated deficit of $215,876,000.
This strategic refocusing on NSCLC treatment represents an important development in oncology research, as non-small cell lung cancer remains a significant health challenge despite advances in immunotherapy. The company's approach to combining L-DOS47 with established immunotherapies could potentially address limitations in current treatment options for lung cancer patients. The progression of LDOS007 through regulatory channels and the company's commitment to this specific therapeutic area may have implications for future cancer treatment paradigms and investor confidence in specialized biopharmaceutical companies targeting high-unmet-need conditions.
